European consensus conference on unruptured brain AVMs treatment (supported by EANS, ESMINT, EGKS, and SINCH)

Marco Cenzato, Edoardo Boccardi, Ettore Beghi, Peter Vajkoczy, Istvan Szikora, Enrico Motti, Luca Regli, Andreas Raabe, Shalva Eliava, Andreas Gruber, Torstein R. Meling, Mika Niemela, Alberto Pasqualin, Andrey Golanov, Bengt Karlsson, Andras Kemeny, Roman Liscak, Bodo Lippitz, Matthias Radatz, Alessandro La Camera & 7 others René Chapot, Civan Islak, Laurent Spelle, Alberto Debernardi, Elio Agostoni, Martina Revay, Michael K. Morgan

Research output: Contribution to journalOther journal contributionResearchpeer-review

Abstract

In December of 2016, a Consensus Conference on unruptured AVM treatment, involving 24 members of the three European societies dealing with the treatment of cerebral AVMs (EANS, ESMINT, and EGKS) was held in Milan, Italy. The panel made the following statements and general recommendations: (1) Brain arteriovenous malformation (AVM) is a complex disease associated with potentially severe natural history; (2) The results of a randomized trial (ARUBA) cannot be applied equally for all unruptured brain arteriovenous malformation (uBAVM) and for all treatment modalities; (3) Considering the multiple treatment modalities available, patients with uBAVMs should be evaluated by an interdisciplinary neurovascular team consisting of neurosurgeons, neurointerventionalists, radiosurgeons, and neurologists experienced in the diagnosis and treatment of brain AVM; (4) Balancing the risk of hemorrhage and the associated restrictions of everyday activities related to untreated unruptured AVMs against the risk of treatment, there are sufficient indications to treat unruptured AVMs grade 1 and 2 (Spetzler–Martin); (5) There may be indications for treating patients with higher grades, based on a case-to-case consensus decision of the experienced team; (6) If treatment is indicated, the primary strategy should be defined by the multidisciplinary team prior to the beginning of the treatment and should aim at complete eradication of the uBAVM; (7) After having considered the pros and cons of a randomized trial vs. a registry, the panel proposed a prospective European Multidisciplinary Registry.

LanguageEnglish
Pages1059-1064
Number of pages6
JournalActa Neurochirurgica
Volume159
Issue number6
DOIs
Publication statusPublished - Jun 2017

Fingerprint

Arteriovenous Malformations
Brain
Therapeutics
Registries
Natural History
Italy
Hemorrhage

Keywords

  • unruptured brain AVM
  • arteriovenous malformation
  • Consensus Conference
  • EANS
  • EGKS
  • ESMINT
  • ARUBA

Cite this

Cenzato, M., Boccardi, E., Beghi, E., Vajkoczy, P., Szikora, I., Motti, E., ... Morgan, M. K. (2017). European consensus conference on unruptured brain AVMs treatment (supported by EANS, ESMINT, EGKS, and SINCH). Acta Neurochirurgica, 159(6), 1059-1064. https://doi.org/10.1007/s00701-017-3154-8
Cenzato, Marco ; Boccardi, Edoardo ; Beghi, Ettore ; Vajkoczy, Peter ; Szikora, Istvan ; Motti, Enrico ; Regli, Luca ; Raabe, Andreas ; Eliava, Shalva ; Gruber, Andreas ; Meling, Torstein R. ; Niemela, Mika ; Pasqualin, Alberto ; Golanov, Andrey ; Karlsson, Bengt ; Kemeny, Andras ; Liscak, Roman ; Lippitz, Bodo ; Radatz, Matthias ; La Camera, Alessandro ; Chapot, René ; Islak, Civan ; Spelle, Laurent ; Debernardi, Alberto ; Agostoni, Elio ; Revay, Martina ; Morgan, Michael K. / European consensus conference on unruptured brain AVMs treatment (supported by EANS, ESMINT, EGKS, and SINCH). In: Acta Neurochirurgica. 2017 ; Vol. 159, No. 6. pp. 1059-1064.
@article{cfced42fac9c4695ac25b4b0bc4d4aca,
title = "European consensus conference on unruptured brain AVMs treatment (supported by EANS, ESMINT, EGKS, and SINCH)",
abstract = "In December of 2016, a Consensus Conference on unruptured AVM treatment, involving 24 members of the three European societies dealing with the treatment of cerebral AVMs (EANS, ESMINT, and EGKS) was held in Milan, Italy. The panel made the following statements and general recommendations: (1) Brain arteriovenous malformation (AVM) is a complex disease associated with potentially severe natural history; (2) The results of a randomized trial (ARUBA) cannot be applied equally for all unruptured brain arteriovenous malformation (uBAVM) and for all treatment modalities; (3) Considering the multiple treatment modalities available, patients with uBAVMs should be evaluated by an interdisciplinary neurovascular team consisting of neurosurgeons, neurointerventionalists, radiosurgeons, and neurologists experienced in the diagnosis and treatment of brain AVM; (4) Balancing the risk of hemorrhage and the associated restrictions of everyday activities related to untreated unruptured AVMs against the risk of treatment, there are sufficient indications to treat unruptured AVMs grade 1 and 2 (Spetzler–Martin); (5) There may be indications for treating patients with higher grades, based on a case-to-case consensus decision of the experienced team; (6) If treatment is indicated, the primary strategy should be defined by the multidisciplinary team prior to the beginning of the treatment and should aim at complete eradication of the uBAVM; (7) After having considered the pros and cons of a randomized trial vs. a registry, the panel proposed a prospective European Multidisciplinary Registry.",
keywords = "unruptured brain AVM, arteriovenous malformation, Consensus Conference, EANS, EGKS, ESMINT, ARUBA",
author = "Marco Cenzato and Edoardo Boccardi and Ettore Beghi and Peter Vajkoczy and Istvan Szikora and Enrico Motti and Luca Regli and Andreas Raabe and Shalva Eliava and Andreas Gruber and Meling, {Torstein R.} and Mika Niemela and Alberto Pasqualin and Andrey Golanov and Bengt Karlsson and Andras Kemeny and Roman Liscak and Bodo Lippitz and Matthias Radatz and {La Camera}, Alessandro and Ren{\'e} Chapot and Civan Islak and Laurent Spelle and Alberto Debernardi and Elio Agostoni and Martina Revay and Morgan, {Michael K.}",
year = "2017",
month = "6",
doi = "10.1007/s00701-017-3154-8",
language = "English",
volume = "159",
pages = "1059--1064",
journal = "Acta Neurochirurgica",
issn = "0001-6268",
publisher = "Springer, Springer Nature",
number = "6",

}

Cenzato, M, Boccardi, E, Beghi, E, Vajkoczy, P, Szikora, I, Motti, E, Regli, L, Raabe, A, Eliava, S, Gruber, A, Meling, TR, Niemela, M, Pasqualin, A, Golanov, A, Karlsson, B, Kemeny, A, Liscak, R, Lippitz, B, Radatz, M, La Camera, A, Chapot, R, Islak, C, Spelle, L, Debernardi, A, Agostoni, E, Revay, M & Morgan, MK 2017, 'European consensus conference on unruptured brain AVMs treatment (supported by EANS, ESMINT, EGKS, and SINCH)', Acta Neurochirurgica, vol. 159, no. 6, pp. 1059-1064. https://doi.org/10.1007/s00701-017-3154-8

European consensus conference on unruptured brain AVMs treatment (supported by EANS, ESMINT, EGKS, and SINCH). / Cenzato, Marco; Boccardi, Edoardo; Beghi, Ettore; Vajkoczy, Peter; Szikora, Istvan; Motti, Enrico; Regli, Luca; Raabe, Andreas; Eliava, Shalva; Gruber, Andreas; Meling, Torstein R.; Niemela, Mika; Pasqualin, Alberto; Golanov, Andrey; Karlsson, Bengt; Kemeny, Andras; Liscak, Roman; Lippitz, Bodo; Radatz, Matthias; La Camera, Alessandro; Chapot, René; Islak, Civan; Spelle, Laurent; Debernardi, Alberto; Agostoni, Elio; Revay, Martina; Morgan, Michael K.

In: Acta Neurochirurgica, Vol. 159, No. 6, 06.2017, p. 1059-1064.

Research output: Contribution to journalOther journal contributionResearchpeer-review

TY - JOUR

T1 - European consensus conference on unruptured brain AVMs treatment (supported by EANS, ESMINT, EGKS, and SINCH)

AU - Cenzato, Marco

AU - Boccardi, Edoardo

AU - Beghi, Ettore

AU - Vajkoczy, Peter

AU - Szikora, Istvan

AU - Motti, Enrico

AU - Regli, Luca

AU - Raabe, Andreas

AU - Eliava, Shalva

AU - Gruber, Andreas

AU - Meling, Torstein R.

AU - Niemela, Mika

AU - Pasqualin, Alberto

AU - Golanov, Andrey

AU - Karlsson, Bengt

AU - Kemeny, Andras

AU - Liscak, Roman

AU - Lippitz, Bodo

AU - Radatz, Matthias

AU - La Camera, Alessandro

AU - Chapot, René

AU - Islak, Civan

AU - Spelle, Laurent

AU - Debernardi, Alberto

AU - Agostoni, Elio

AU - Revay, Martina

AU - Morgan, Michael K.

PY - 2017/6

Y1 - 2017/6

N2 - In December of 2016, a Consensus Conference on unruptured AVM treatment, involving 24 members of the three European societies dealing with the treatment of cerebral AVMs (EANS, ESMINT, and EGKS) was held in Milan, Italy. The panel made the following statements and general recommendations: (1) Brain arteriovenous malformation (AVM) is a complex disease associated with potentially severe natural history; (2) The results of a randomized trial (ARUBA) cannot be applied equally for all unruptured brain arteriovenous malformation (uBAVM) and for all treatment modalities; (3) Considering the multiple treatment modalities available, patients with uBAVMs should be evaluated by an interdisciplinary neurovascular team consisting of neurosurgeons, neurointerventionalists, radiosurgeons, and neurologists experienced in the diagnosis and treatment of brain AVM; (4) Balancing the risk of hemorrhage and the associated restrictions of everyday activities related to untreated unruptured AVMs against the risk of treatment, there are sufficient indications to treat unruptured AVMs grade 1 and 2 (Spetzler–Martin); (5) There may be indications for treating patients with higher grades, based on a case-to-case consensus decision of the experienced team; (6) If treatment is indicated, the primary strategy should be defined by the multidisciplinary team prior to the beginning of the treatment and should aim at complete eradication of the uBAVM; (7) After having considered the pros and cons of a randomized trial vs. a registry, the panel proposed a prospective European Multidisciplinary Registry.

AB - In December of 2016, a Consensus Conference on unruptured AVM treatment, involving 24 members of the three European societies dealing with the treatment of cerebral AVMs (EANS, ESMINT, and EGKS) was held in Milan, Italy. The panel made the following statements and general recommendations: (1) Brain arteriovenous malformation (AVM) is a complex disease associated with potentially severe natural history; (2) The results of a randomized trial (ARUBA) cannot be applied equally for all unruptured brain arteriovenous malformation (uBAVM) and for all treatment modalities; (3) Considering the multiple treatment modalities available, patients with uBAVMs should be evaluated by an interdisciplinary neurovascular team consisting of neurosurgeons, neurointerventionalists, radiosurgeons, and neurologists experienced in the diagnosis and treatment of brain AVM; (4) Balancing the risk of hemorrhage and the associated restrictions of everyday activities related to untreated unruptured AVMs against the risk of treatment, there are sufficient indications to treat unruptured AVMs grade 1 and 2 (Spetzler–Martin); (5) There may be indications for treating patients with higher grades, based on a case-to-case consensus decision of the experienced team; (6) If treatment is indicated, the primary strategy should be defined by the multidisciplinary team prior to the beginning of the treatment and should aim at complete eradication of the uBAVM; (7) After having considered the pros and cons of a randomized trial vs. a registry, the panel proposed a prospective European Multidisciplinary Registry.

KW - unruptured brain AVM

KW - arteriovenous malformation

KW - Consensus Conference

KW - EANS

KW - EGKS

KW - ESMINT

KW - ARUBA

UR - http://www.scopus.com/inward/record.url?scp=85017150000&partnerID=8YFLogxK

U2 - 10.1007/s00701-017-3154-8

DO - 10.1007/s00701-017-3154-8

M3 - Other journal contribution

VL - 159

SP - 1059

EP - 1064

JO - Acta Neurochirurgica

T2 - Acta Neurochirurgica

JF - Acta Neurochirurgica

SN - 0001-6268

IS - 6

ER -